Free Trial

IN8bio (INAB) Competitors

IN8bio logo
$2.10 -0.08 (-3.67%)
Closing price 04:00 PM Eastern
Extended Trading
$2.19 +0.09 (+4.29%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INAB vs. TPST, CARA, TENX, LSTA, CYTH, FBLG, KLTO, NNVC, BCAB, and SNYR

Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), NanoViricides (NNVC), BioAtla (BCAB), and Synergy CHC (SNYR). These companies are all part of the "pharmaceutical products" industry.

IN8bio vs. Its Competitors

IN8bio (NASDAQ:INAB) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

IN8bio's return on equity of -218.85% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
IN8bioN/A -218.85% -139.59%
Tempest Therapeutics N/A -305.51%-119.74%

IN8bio presently has a consensus price target of $180.00, indicating a potential upside of 8,471.43%. Tempest Therapeutics has a consensus price target of $30.00, indicating a potential upside of 323.73%. Given IN8bio's stronger consensus rating and higher possible upside, research analysts plainly believe IN8bio is more favorable than Tempest Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IN8bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tempest Therapeutics
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Tempest Therapeutics had 3 more articles in the media than IN8bio. MarketBeat recorded 3 mentions for Tempest Therapeutics and 0 mentions for IN8bio. Tempest Therapeutics' average media sentiment score of 0.41 beat IN8bio's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
IN8bio Neutral
Tempest Therapeutics Neutral

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by insiders. Comparatively, 4.7% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tempest Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IN8bioN/AN/A-$30.44M-$13.57-0.15
Tempest TherapeuticsN/AN/A-$41.84M-$17.98-0.39

Summary

IN8bio beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INAB vs. The Competition

MetricIN8bioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.60M$2.92B$5.53B$9.03B
Dividend YieldN/A2.44%5.24%4.01%
P/E Ratio-0.157.5519.3119.89
Price / SalesN/A284.29424.59117.07
Price / CashN/A41.7026.2128.59
Price / Book0.357.397.925.55
Net Income-$30.44M-$55.04M$3.17B$248.49M
7 Day Performance0.48%3.01%2.18%5.37%
1 Month Performance-49.64%-0.21%1.25%6.63%
1 Year Performance-91.25%4.48%33.90%21.20%

IN8bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INAB
IN8bio
2.2931 of 5 stars
$2.10
-3.7%
$180.00
+8,471.4%
-90.7%$6.60MN/A-0.1520
TPST
Tempest Therapeutics
1.6221 of 5 stars
$6.80
-1.4%
$30.00
+341.2%
-72.8%$25.41MN/A-0.3820
CARA
Cara Therapeutics
0.3381 of 5 stars
N/AN/AN/A$24.33M$7.14M-0.2580Gap Down
High Trading Volume
TENX
Tenax Therapeutics
1.2486 of 5 stars
$5.76
-1.5%
$17.50
+203.8%
+88.0%$24.27MN/A-2.329
LSTA
Lisata Therapeutics
2.4741 of 5 stars
$2.90
+3.6%
$15.00
+417.2%
-24.8%$24.12M$1M-1.2630Positive News
CYTH
Cyclo Therapeutics
N/A$0.72
flat
$0.95
+31.8%
N/A$23.72M$870.73K-0.809
FBLG
FibroBiologics
2.522 of 5 stars
$0.62
+0.7%
$13.00
+1,989.4%
-87.0%$23.65MN/A0.0010News Coverage
Gap Up
KLTO
Klotho Neurosciences
N/A$1.13
+56.9%
N/AN/A$23.40MN/A0.00N/AAnalyst Upgrade
Gap Down
High Trading Volume
NNVC
NanoViricides
1.0921 of 5 stars
$1.40
flat
N/A-20.0%$22.50MN/A-1.9420News Coverage
Positive News
BCAB
BioAtla
2.715 of 5 stars
$0.40
+3.1%
$5.00
+1,162.6%
-71.2%$22.43M$11M-0.3260
SNYR
Synergy CHC
3.5869 of 5 stars
$2.85
+17.3%
$10.00
+250.9%
N/A$22.34M$34.83M0.0040Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:INAB) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners